Clinical trials: Left Ventricular Failure
End-Stage Renal Disease
Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis
This study aims to compare high-efficiency post-dilution on-line hemodiafiltration and high-flux hemodialysis regarding mortality, hospitalization rate, several clinical and laboratory parameters, and required medications.
- Trial name
- NCT00411177
- Testing
- post-dilution on-line hemodiafiltration, high flux hemodialysis
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 782 people
- Sponsor
- Ercan OK
Heart Failure, Heart Failure With Reduced Ejection Fraction
AI-ECG for Time-Resolved Prediction of HFrEF
This study aims to develop and validate a deep learning-based electrocardiogram (ECG) model for predicting the future risk of heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Left Ventricular Dysfunction, Cardiac Remodeling
- Trial name
- NCT07519434
- Where
- China
- Volunteers
- 286,709 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Heart Failure
Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction
Background: Heart failure with preserved ejection fraction (HFPEF) is common but not well understood. Electrical dyssynchrony in systolic heart failure is harmful.
- Trial name
- KaRen (NCT00774709)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- French Cardiology Society
Chronic Heart Failure, Iron-deficiency
Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure
The goal of this study is to investigate the effect of oral sucrosomial iron on exercise capacity and quality of life in patients with heart failure (HF) and iron deficiency (ID).
- Conditions
- Chronic Heart Failure, Iron-deficiency, Left Ventricular Systolic Dysfunction
- Trial name
- RISE-HF (NCT06270498)
- Testing
- Sucrosomial iron
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Raffaele De Caterina
Myocardial Infarction, Heart Failure
A Study of VentriGel in Post-MI Patients
This Phase I, open label, study will investigate the effects of VentriGel injection in patients who have experienced a first, large ST elevation myocardial infarction (STEMI) treated by PCI within the past 3 years and have…
- Conditions
- Myocardial Infarction, Heart Failure, Left Ventricular Remodeling
- Trial name
- NCT02305602
- Testing
- VentriGel
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ventrix, Inc.
Heart Failure
The Determination of Important Mechanical Patterns of Left Ventricular Efficiency-MV02 Study
The purpose of this study is to determine if analysis of heart ultrasound images with new software programs will provide better understanding as to the specific heart problems that lead to symptoms of heart failure.
- Trial name
- DIMPLE (NCT01807819)
- Testing
- Heart Failure
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Florida
Congestive Heart Failure, Left Ventricular Ejection Fraction
Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to examine electrical and echocardiographic characteristics and prognosis of consecutive patients admitted with acute heart failure and diagnosed to have heart failure with preserved ejection fraction…
- Conditions
- Congestive Heart Failure, Left Ventricular Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- KaRen (NCT01091467)
- Where
- 2 sites in France, Sweden
- Volunteers
- 362 people
- Sponsor
- French Cardiology Society
Hypertrophic Cardiomyopathy
Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
The purpose of this study is to determine if a drug called atorvastatin will reduce the size and stiffness of the muscle in the left ventricle of the heart.
- Trial name
- NCT00317967
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy
Optimizing Left Ventricular Lead To Improve Cardiac Output
The purpose of this study is to determine if optimal lead placement, guided by the largest improvement in aortic flow measured by Doppler will: 1. Improve the way the heart's left ventricle functions 2.
- Conditions
- Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
- Trial name
- CARE/VOLCANO (NCT01399801)
- Testing
- Doppler flow measurement, standard implantation of the LV lead
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ann Marie Chikowski
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
- Trial name
- PRIMO II (NCT00616902)
- Testing
- paricalcitol injection 4 mcg/mL
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 12 people
- Sponsor
- Abbott
Heart Failure
Optimal Left Ventricular Lead Positioning During Cardiac Resynchronisation Therapy; Comparison of Two Methods of Targeting
Cardiac Resynchronisation Therapy (CRT) is a well-known treatment for patients with heart failure. It is a special pacemaker that consists of three pacing wires, which are implanted in the right upper and bottom chambers of the…
- Trial name
- NCT03769272
- Testing
- Measurement of electrical delay during LV lead placement
- Volunteers
- 40 people
- Sponsor
- Peter J Pugh
Heart Failure, Ventricular Dysfunction
Safety and Performance of Electrodes Implanted in the Left Ventricle
The study is intended to demonstrate the safe implant of small receiver-electrodes into the endocardial surface of the left ventricle and to demonstrate its utility in providing cardiac resynchronization therapy in heart failure…
- Conditions
- Heart Failure, Ventricular Dysfunction, Cardiomyopathies, Heart Diseases
- Trial name
- SELECT-LV (NCT01905670)
- Testing
- WiCS-LV system
- Where
- 2 sites in Czechia, Denmark
- Volunteers
- 39 people
- Sponsor
- EBR Systems, Inc.
Heart Failure, Systolic
Patient and Physician Survey Determinants of Appropriate ICD Utilization
To better understand the reasons for underutilization of defibrillator therapy in selected populations, the investigators propose a study to assess heart failure patient knowledge and attitudes toward device therapy.
- Trial name
- NCT01514773
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Todd M Koelling, MD
Heart Failure
EASYTRAK 3 Downsize Lead
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the EASYTRAK 3 Downsize Lead.
- Trial name
- NCT00384722
- Testing
- EASYTRAK 3 Downsize Lead
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Cardiac Magnetic Resonance Imaging Guided Left Ventricular Lead Placement
Heart failure is a common, costly, disabling and potentially lethal condition. Despite well recognised and proven drug therapies, many patients remain breathless on exertion.
- Trial name
- NCT01417624
- Testing
- CMR Guidance in terms of guiding LV lead implantation
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Heart Failure and Reduced Ejection Fraction, Heart Failure
PRIMA-HF: Predicting Myocardial Recovery in Heart Failure Using Cardiac Imaging HAI-HF: High Dosing vs. Standard Dosing Adenosine During Myocardial Perfusion in Heart Failure
Background: Heart failure with reduced ejection fraction (HFrEF) is a heterogeneous condition with variable potential for left ventricular ejection fraction (LVEF) recovery.
- Trial name
- PRIMA-HF (NCT07243119)
- Testing
- HAI-HF: Adenosine Stress [¹⁵O]H₂O PET Imaging, Two different doses of adenosine
- Where
- Denmark
- Volunteers
- 180 people
- Sponsor
- Gødstrup Hospital
Idiopathic Cardiomyopathy, Left Ventricular (LV) Systolic Dysfunction
Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead
Patients with idiopathic dilated cardiomyopathy in heart failure (NYHA class III - IV) with a baseline left ventricular ejection fraction between ≥25% and ≤35%, and patients with non-ischemic cardiomyopathy in heart failure (NYHA…
- Conditions
- Idiopathic Cardiomyopathy, Left Ventricular (LV) Systolic Dysfunction, Non-ischemic Cardiomyopathy
- Trial name
- NCT06920030
- Testing
- Subcutaneous cardiac microcurrent treatment
- Where
- 4 sites in Bosnia and Herzegovina, Serbia
- Volunteers
- 22 people
- Sponsor
- Berlin Heals GmbH
End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT)
Development & Testing of a Decision Aid for LVAD Placement
The goal of this project is to develop a patient-centered decision aid for decision-making about end-stage heart failure treatment.
- Conditions
- End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT), Destination Therapy LVAD Placement (DT), Refusal of LVAD Placement (Decliners)
- Trial name
- VADDA (NCT02248974)
- Testing
- LVAD Decision Aid
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- Baylor College of Medicine
Heart Failure With Normal Ejection Fraction
Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
StiffMAP-HFpEF trial is an investigator initiated, observational, single-center study that will evaluate whether fibrosis quantification by cardiac MRI correlates with left and right ventricular stiffness derived from…
- Trial name
- STIFFMAP (NCT02459626)
- Testing
- Diagnostic P-V-loops and MRI
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Heart Center Leipzig - University Hospital
Renal Failure, Left Ventricular Hypertrophy
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic…
- Trial name
- NCT00602004
- Testing
- losartan
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Melbourne Health